Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.

Bausch + Lomb Announces Launch of EZ-24 Easy-Load Lens Delivery System for SofPort® Advanced Optics Intraocular Lenses



BRIDGEWATER, NJ – Bausch + Lomb, a leading global eye health company, today announced the launch of the EZ-24 Easy-Load lens delivery system, which is designed exclusively for use with the SofPort® Advanced Optics (AO) intraocular lens (IOL).  The EZ-24 Easy-Load lens delivery system facilitates smooth and easy delivery of the SofPort® IOL through a 2.4mm incision.


This new delivery system features a smooth oval tip designed for ease of wound entry, reliability and control.  Combining the benefits of sterile, single-use “no-touch” lens loading design with Bausch + Lomb’s proprietary planar delivery, the device facilitates direct placement of the SofPort® IOL (LI61AO and LI61SE) into the capsular bag, minimizing tissue trauma and related potential complications compared to traditional IOL insertion through primary incisions in the cornea. Additionally, its M-folded delivery gives the physician excellent control on lens delivery in the bag.


“Bausch + Lomb collaborated with surgeons and technicians around the country to design the new EZ-24 Easy-Load lens delivery system,” said Andrew Chang, senior vice president and general manager, U.S. Surgical, Bausch + Lomb. “We routinely work together with our customers to identify new enhancements and improvements that best support them and the patients they serve. The EZ-24 injector is just one example of how we integrate the needs of our customers—not just with new products, but with continued enhancements to existing products as well.”


“As a surgeon who has implanted countless SofPort® IOLs over the years, I’m pleased to have an injector that enables small-incision surgery while providing excellent control and smooth entry at the time of IOL implantation,” said Sheri Rowen, M.D., from NVISION Eye Centers in Newport Beach, CA. “It is both beneficial and efficient to eliminate expanding the primary incision for larger IOL implantation, thus reducing surgically induced astigmatism, and improving incision closure.”1


Implanted in millions of eyes around the world, the SofPort® AO IOL features aberration-free aspheric optics, providing cataract patients with excellent postoperative vision quality and contrast sensitivity without reducing depth of field or inducing aberrations when decentered.2 The lens also includes a 360-degree posterior square edge. This design feature has been shown to reduce Posterior Capsular Opacification (PCO), a common post-surgical complication with IOLs that causes vision to become cloudy post-surgery.3

About Bausch + Lomb:
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry with products available in more than 100 countries. 


1. Tetikoglu, Mehmet et. al. Effect of Corneal Incision Enlargement on Surgically Induced Astigmatism in Biaxial Microincision Cataract Surgery. Turkish Journal of Ophthalmology, 2016; 34: 99-103.

2. Altmann, Griffith E, et. al. Optical Performance of 3 Intraocular Lens Designs in the Presence of Decentration. J Cataract Refractive Surgery, 2005;31:574-585.

3. Buehl, Wolf and Findl, Oliver. Effect of Intraocular Lens Design on Posterior Capsule Opacification. J Cataract Refractive Surgery, 2008; 34:1976-1985.


SofPort is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2016 Bausch & Lomb Incorporated.


News Media Contacts:
Kristy Marks
PR Product Manager, Bausch + Lomb
(585) 338-8095 or

Teresa Panas
BioComm Network, on behalf of Bausch + Lomb
(973) 809-8590 or

Michele Gray
BioComm Network, on behalf of Bausch + Lomb
(917) 449-9250 or

Actions: E-mail | Permalink |